Literature DB >> 12900340

Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution.

Israel M Barbash1, Pierre Chouraqui, Jack Baron, Micha S Feinberg, Sharon Etzion, Ariel Tessone, Liron Miller, Esther Guetta, Dov Zipori, Laurence H Kedes, Robert A Kloner, Jonathan Leor.   

Abstract

BACKGROUND: Systemic delivery of bone marrow-derived mesenchymal stem cells (BM-MSCs) is an attractive approach for myocardial repair. We aimed to test this strategy in a rat model after myocardial infarction (MI). METHODS AND
RESULTS: BM-MSCs were obtained from rat bone marrow, expanded in vitro to a purity of >50%, and labeled with 99mTc exametazime, fluorescent dye, LacZ marker gene, or bromodeoxyuridine. Rats were subjected to MI by transient coronary artery occlusion or to sham MI. 99mTc-labeled cells (4x10(6)) were transfused into the left ventricular cavity of MI rats either at 2 or 10 to 14 days after MI and were compared with sham-MI rats or MI rats treated with intravenous infusion. Gamma camera imaging and isolated organ counting 4 hours after intravenous infusion revealed uptake of the 99mTc-labeled cells mainly in the lungs, with significantly smaller amounts in the liver, heart, and spleen. Delivery by left ventricular cavity infusion resulted in drastically lower lung uptake, better uptake in the heart, and specifically higher uptake in infarcted compared with sham-MI hearts. Histological examination at 1 week after infusion identified labeled cells either in the infarcted or border zone but not in remote viable myocardium or sham-MI hearts. Labeled cells were also identified in the lung, liver, spleen, and bone marrow.
CONCLUSIONS: Systemic intravenous delivery of BM-MSCs to rats after MI, although feasible, is limited by entrapment of the donor cells in the lungs. Direct left ventricular cavity infusion enhances migration and colonization of the cells preferentially to the ischemic myocardium.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12900340     DOI: 10.1161/01.CIR.0000084828.50310.6A

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  396 in total

Review 1.  Advances in cardiovascular molecular imaging for tracking stem cell therapy.

Authors:  Katherine J Ransohoff; Joseph C Wu
Journal:  Thromb Haemost       Date:  2010-05-10       Impact factor: 5.249

2.  Bioinspired nanofibers support chondrogenesis for articular cartilage repair.

Authors:  Jeannine M Coburn; Matthew Gibson; Sean Monagle; Zachary Patterson; Jennifer H Elisseeff
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-04       Impact factor: 11.205

Review 3.  Concise review: mesoangioblast and mesenchymal stem cell therapy for muscular dystrophy: progress, challenges, and future directions.

Authors:  Suzanne E Berry
Journal:  Stem Cells Transl Med       Date:  2014-11-12       Impact factor: 6.940

4.  Bone marrow stromal cells produce long-term pain relief in rat models of persistent pain.

Authors:  Wei Guo; Hu Wang; Shiping Zou; Ming Gu; Mineo Watanabe; Feng Wei; Ronald Dubner; George T-J Huang; Ke Ren
Journal:  Stem Cells       Date:  2011-08       Impact factor: 6.277

5.  Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.

Authors:  D Ladage; I C Turnbull; K Ishikawa; Y Takewa; K Rapti; C Morel; I Karakikes; L Hadri; J Müller-Ehmsen; K D Costa; R J Hajjar; Y Kawase
Journal:  Gene Ther       Date:  2011-04-21       Impact factor: 5.250

6.  Second Annual Mario S. Verani, MD, Memorial Lecture: Nuclear cardiology, the next 10 years.

Authors:  Barry L Zaret
Journal:  J Nucl Cardiol       Date:  2004 Jul-Aug       Impact factor: 5.952

7.  Engineered cell homing.

Authors:  Debanjan Sarkar; Joel A Spencer; Joseph A Phillips; Weian Zhao; Sebastian Schafer; Dawn P Spelke; Luke J Mortensen; Juan P Ruiz; Praveen Kumar Vemula; Rukmani Sridharan; Sriram Kumar; Rohit Karnik; Charles P Lin; Jeffrey M Karp
Journal:  Blood       Date:  2011-10-27       Impact factor: 22.113

Review 8.  SPECT and PET to optimize cardiac stem cell therapy.

Authors:  Angel T Chan; M Roselle Abraham
Journal:  J Nucl Cardiol       Date:  2012-02       Impact factor: 5.952

Review 9.  Mesenchymal stromal cells for cell therapy: besides supporting hematopoiesis.

Authors:  Lei Hao; Huiqin Sun; Jin Wang; Tao Wang; Mingke Wang; Zhongmin Zou
Journal:  Int J Hematol       Date:  2011-12-20       Impact factor: 2.490

10.  Mesenchymal stem cells impair in vivo T-cell priming by dendritic cells.

Authors:  Sabrina Chiesa; Silvia Morbelli; Sara Morando; Michela Massollo; Cecilia Marini; Arinna Bertoni; Francesco Frassoni; Soraya Tabera Bartolomé; Gianmario Sambuceti; Elisabetta Traggiai; Antonio Uccelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-29       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.